ArticleBMC neurology2015
No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients.
Article in BMC neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02883335 (Lorraine Registry of Multiple Sclerosis), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Lorraine Registry of Multiple Sclerosis
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Myelinoclastic diffuse sclerosis (Schilder's disease) is immunologically distinct from multiple sclerosis: results from retrospective analysis of 92 lumbar punctures.Journal of neuroinflammation · 2019Pooled it
- Challenges and Innovation for Diagnosing and Treatment of Secondary Progressive Multiple Sclerosis.International journal of molecular sciences · 2026Review
- Comparative analysis of neuroinflammatory pathways in Alzheimer's disease, Parkinson's disease, and multiple sclerosis: insights into similarities and distinctions.Frontiers in neuroscience · 2025Review
- Fluid biomarkers in multiple sclerosis: from current to future applications.The Lancet regional health. Europe · 2024Review
- Recent progress in epidemiology, clinical features, and therapy of multiple sclerosis in China.Therapeutic advances in neurological disorders · 2023Review
- Current and Future Biomarkers in Multiple Sclerosis.International journal of molecular sciences · 2022Review
- The Evolution of Neurofilament Light Chain in Multiple Sclerosis.Frontiers in neuroscience · 2021Review
- IgG Index Revisited: Diagnostic Utility and Prognostic Value in Multiple Sclerosis.Frontiers in immunology · 2020Article
- Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis.JAMA neurology · 2019Observational
- Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2018Article
- Treatment of Theiler's virus-induced demyelinating disease with teriflunomide.Journal of neurovirology · 2017Article
- Early predictive factors of disability in CIDP.Journal of neurology · 2017Article
- Emerging Approaches for Validating and Managing Multiple Sclerosis Relapse.Frontiers in neurology · 2017Review
- A multi-biomarker follow-up study of patients with multiple sclerosis.Brain and behavior · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to determine the association of clinical and routine cerebrospinal fluid biochemical markers (total protein, IgG index and oligoclonal bands) with disability in multiple sclerosis and whether these biomarkers assessed at diagnosis add prognostic value.
methodsWe followed a cohort of patients included in the Multiple Sclerosis Lorraine Register (eastern France) who had a diagnosis of multiple sclerosis for at least 5 years, as well as biological markers values and MRI findings (Barkhof's criteria). In a Cox regression model, endpoint was time to score of 4 on the Expanded Disability Status Scale (EDSS) (i.e., limited time walking without aid or rest for more than 500 m).
resultsFor 407 patients included, the median time from multiple sclerosis onset to EDSS score 4 was 4.5 years [2.2-7.2]. Cerebrospinal fluid total protein factor < 500 mg/L was associated with EDSS score 4 on bivariate analysis (hazard ratio 0.66, 95% confidence interval 0.46-0.95, p = 0.02). On multivariate analysis, older age at disease onset (≥50 years) and initial primary progressive course of MS but not biological markers predicted worse prognosis.
conclusionRoutine cerebrospinal fluid biological markers at diagnosis were not prognostic factors of multiple sclerosis progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.